Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27246888 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ANPC1P2RX7NHERF1 | |
| SCHEMBL27383517 | 0.92 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1P2RX7METTL3 | |
| SCHEMBL27246735 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1METTL3METTL14 | |
| SCHEMBL30920406 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1METTL3METTL14 | |
| SCHEMBL27247391 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1P2RX7METTL3 | |
| SCHEMBL30920614 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1MEN1LMNA | |
| SCHEMBL30920360 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AMEN1LMNAMAPT | |
| SCHEMBL30920508 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1METTL3METTL14 | |
| SCHEMBL27383273 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1P2RX7METTL3 | |
| SCHEMBL27247882 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | SMN1; SMN2 375/4885RAB9A 105/4885NPC1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.